Ford Motor Company

About: Ford Motor Company is a company organization based out in Dearborn, Michigan, United States. It is known for research contribution in the topics: Internal combustion engine & Signal. The organization has 36123 authors who have published 51450 publications receiving 855200 citations. The organization is also known as: Ford Motor & Ford Motor Corporation.

Enhanced thermal conductivity and viscosity of copper nanoparticles in ethylene glycol nanofluid

Abstract: This study investigates the thermal conductivity and viscosity of copper nanoparticles in ethylene glycol. The nanofluid was prepared by synthesizing copper nanoparticles using a chemical reduction method, with water as the solvent, and then dispersing them in ethylene glycol using a sonicator. Volume loadings of up to 2% were prepared. The measured increase in thermal conductivity was twice the value predicted by the Maxwell effective medium theory. The increase in viscosity was about four times of that predicted by the Einstein law of viscosity. Analytical calculations suggest that this nanofluid would not be beneficial as a coolant in heat exchangers without changing the tube diameter. However, increasing the tube diameter to exploit the increased thermal conductivity of the nanofluid can lead to better thermal performance.

Rheology of magnetorheological fluids: models and measurements

Abstract: Numerical and analytical models of magnetorheological fluid phenomena that account explicitly for the effects of magnetic nonlinearity and saturation are described. Finite-element analysis was used to calculate the field distribution in chains of magnetizable particles. The field-dependent stress required to shear the chains was then obtained using the Maxwell stress tensor. Three regimes are identified: at low applied fields, the stress increase quadratically, as expected from linear magnetostatics. In intermediate fields, the contact or polar regions of each particle saturate, reducing the rate of increase of the stress with increasing field. At high fields, the particles saturate completely, and the stress reaches its limiting value. Approximate analytical expressions for the yield stress and shear modulus in these regimes are also derived. The predictions of these models are compared to magnetorheological experiments in the literature and from our laboratory. These models predict successfully the magn...

Light Emission from Inelastic Electron Tunneling

Abstract: We report the discovery of a new method for the generation of light. This technique yields a broad-band light source with a high frequency linear cutoff which is dependent only upon the applied voltage through the quantum relation $h{\ensuremath{ u}}_{\mathrm{co}}=|\mathrm{eV}|$. The light source consists of a metal-insulator-metal tunneling junction. The effect can be interpreted in terms of inelastic tunneling excitation of optically coupled surface plasmon modes.

Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

Abstract: STUDY OBJECTIVES To determine the long-term efficacy of eszopiclone in patients with chronic insomnia. DESIGN Randomized, double-blind, multicenter, placebo-controlled. SETTING Out-patient, with monthly visits. PATIENTS Aged 21 to 69 years meeting DSM IV criteria for primary insomnia and reporting less than 6.5 hours of sleep per night, and/or a sleep latency of more than 30 minutes each night for at least 1 month before screening. INTERVENTIONS Eszopiclone 3 mg (n = 593) or placebo (n = 195), nightly for 6 months MEASUREMENTS AND RESULTS Efficacy was evaluated weekly using an interactive voice-response system. Endpoints included sleep latency; total sleep time; number of awakenings; wake time after sleep onset; quality of sleep; and next-day ratings of ability to function, daytime alertness, and sense of physical well-being. At the first week and each month for the study duration, eszopiclone produced significant and sustained improvements in sleep latency, wake time after sleep onset, number of awakenings, number of nights awakened per week, total sleep time, and quality of sleep compared with placebo (P < or = 0.003). Monthly ratings of next-day function, alertness, and sense of physical well-being were also significantly better with the use of eszopiclone than with placebo (P < or = 0.002). There was no evidence of tolerance, and the most common adverse events were unpleasant taste and headache. CONCLUSIONS Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function. This placebo-controlled study of eszopiclone provides compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.